Does Your Own Melatonin Clear the Brain? A Critical Review Finds the Question Untested
A critical review finds no study has tested whether the body's own melatonin drives brain clearance; positive results used doses 40 to 900 times standard.
Summary
Melatonin has been proposed as a helper for clearing amyloid-beta and tau, the proteins tied to Alzheimer's disease, and its age-related decline has been blamed for clearance failure. This critical narrative review asked what the evidence can actually support, separating the body's own pineal melatonin from melatonin given as a treatment. It found that no study has manipulated the body's own melatonin while measuring brain clearance, so a causal role is untested. The positive animal findings used administered melatonin at exposures far above standard supplement doses: about 40 to 900 times after body-surface-area adjustment. Rodents are also nocturnal while humans are diurnal, which complicates translation, and humans lack a validated non-invasive way to measure brain clearance. The mechanism remains plausible but unproven, and these results do not justify routine supplementation for dementia prevention.
Detailed Summary
Why this matters: Brain clearance, the process by which fluid moves along blood vessels to carry away waste such as amyloid-beta and tau, is a leading idea in dementia biology. Melatonin falls with age and in Alzheimer's disease, so it has been proposed as a driver of clearance failure and a possible prevention tool.
What was studied: This critical narrative review searched MEDLINE via PubMed, Scopus and the Cochrane Library from inception to August 2026, with an update in October 2026. The authors appraised studies by what was actually manipulated: the organism's own pineal output, administered melatonin at physiological or higher exposure, or actions that do not require receptor occupancy. Animal doses were converted to human-equivalent doses by body-surface-area normalization.
Key results: In the literature identified, no study manipulated endogenous pineal melatonin while measuring perivascular transport or clearance. None combined a melatonin receptor antagonist or receptor deletion with a clearance readout. A causal role for the body's own melatonin is therefore untested. Positive preclinical findings used administered melatonin at exposures estimated at two to four orders of magnitude above standard clinical dosing by body weight, and roughly 40 to 900 times standard dosing after surface-area normalization.
Implications: The evidence is consistent with pharmacological modulation of parts of the clearance system, which is a mechanistic signal worth tracking. It does not show that normal nighttime melatonin regulates clearance, nor that standard supplements do. The authors suggest pinealectomy with timed replacement in a melatonin-proficient animal, plus a receptor antagonist arm in existing designs, to close the main gaps.
Caveats: Melatonin secretion timing relative to sleep-associated clearance differs between nocturnal rodents and diurnal humans. Human work lacks a validated non-invasive clearance measure. This is a narrative review, and this summary rests on the abstract only.
Key Findings
- No identified study manipulated endogenous pineal melatonin while measuring brain clearance, so its causal role remains untested.
- No study paired a melatonin receptor antagonist or receptor deletion with a clearance readout.
- Positive preclinical results used administered melatonin at roughly 40 to 900 times standard dosing after body-surface-area normalization.
- Rodent nocturnal versus human diurnal melatonin timing constrains translation of sleep-linked clearance findings.
Methodology
Critical narrative review searching MEDLINE via PubMed, Scopus and the Cochrane Library through August 2026, with an update search in October 2026. Studies were classified by what was manipulated (endogenous pineal output, administered melatonin, or receptor-independent actions) and by design strength. Animal doses were converted to human-equivalent doses by body-surface-area normalization.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. The review is narrative rather than a quantitative meta-analysis, and its conclusions reflect gaps in the primary literature, including no validated non-invasive human clearance measure. Dose conversion by body-surface area carries its own acknowledged limitations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
